For the year ending 2025-12-31, RGEN had -$191,334K decrease in cash & cash equivalents over the period. $93,898K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 738,256 |
| Cost of goods sold | 352,011 |
| Research and development | 54,177 |
| Sales and marketing | 105,320 |
| General and administrative | 171,581 |
| Total costs and operating expenses | 683,089 |
| Other income (expenses), net | 7,216 |
| Income tax provision (benefit) | 13,489 |
| Net (loss) income | 48,894 |
| Depreciation and amortization | 78,745 |
| Amortization of debt discount and issuance costs | 16,646 |
| Inventory step-up amortization | 1,560 |
| Stock-based compensation | 32,605 |
| Deferred income taxes, net | -3,373 |
| Change in fair value of contingent consideration | -13,607 |
| Non-cash interest income | 0 |
| Loss on extinguishment of debt | 0 |
| Net unrealized foreign exchange gain | 13,014 |
| Operating lease right of use asset amortization | 18,211 |
| Other adjustments and non-cash items | -1,630 |
| Accounts receivable | 17,165 |
| Inventories | 14,947 |
| Prepaid expenses and other current assets | 7,756 |
| Other noncurrent assets | 1,560 |
| Accounts payable | -4,150 |
| Accrued liabilities | 11,813 |
| Operating lease liabilities | -15,556 |
| Noncurrent liabilities | -1,559 |
| Total cash provided by operating activities | 117,417 |
| Acquisitions, net of cash acquired | 70,328 |
| Purchases of marketable securities | 200,257 |
| Maturities of marketable securities | 0 |
| Additions to capitalized software costs | 2,211 |
| Purchases of property, plant and equipment | 23,519 |
| Sale of property, plant and equipment | 238 |
| Purchase of intellectual property | 0 |
| Other investing activities | 2,397 |
| Total cash used in investing activities | -298,474 |
| Repurchase of common stock | 0 |
| Proceeds from issuance of 2023 notes | 0 |
| Proceeds from exercise of stock options | 3,176 |
| Payment of debt issuance costs | 0 |
| Payment of tax withholding obligation on vesting of restricted stock | 8,833 |
| Repayment of 2019 notes | 0 |
| Payment of earnout consideration | 9,548 |
| Other financing activities | 0 |
| Total cash (used in) provided by financing activities | -15,205 |
| Effect of exchange rate changes on cash and cash equivalents | 4,928 |
| Net (decrease) increase in cash and cash equivalents | -191,334 |
| Cash and cash equivalents, beginning of period | 757,355 |
| Cash and cash equivalents, end of period | 566,021 |
REPLIGEN CORP (RGEN)
REPLIGEN CORP (RGEN)